Minurin (Desmopressin Acetate)

Desmopressin is a synthetic analogue of the natural hormone vasopressin. It selectively activates V2 receptors in the kidney, which triggers a cascade that inserts aquaporin‑2 channels into the collecting‑duct cells, allowing more water to be reabsorbed. In blood vessels, V2 activation releases stored clotting factors, improving haemostasis.

The appropriate dose of Minurin is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function, and response to therapy. Dosage regimens are not standardized in public literature and must be set by a qualified healthcare professional.

Safety data for desmopressin in pregnancy are limited. It should only be used when the potential benefit justifies any possible risk to the fetus. Desmopressin is excreted in breast milk in small amounts; nursing mothers should discuss risks and benefits with their physician before continuing therapy.

To request Minurin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and assistance with import documentation.

For diabetes insipidus, desmopressin offers a more selective V2‑receptor profile than natural vasopressin, reducing vasoconstrictive side effects. In bleeding disorders, it provides a non‑replacement option compared with factor concentrates, useful for mild hemophilia A or von Willebrand disease. Oral desmopressin formulations exist, but the injectable form allows precise dosing in acute settings.

Minurin should be stored at room temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and avoid freezing. Do not use the product if the solution appears discolored or contains particles.

Minurin is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously, depending on the clinical situation and physician preference. Administration techniques follow standard aseptic injection practices, and the dose is adjusted by the prescriber according to the therapeutic goal.

The most critical safety concerns involve water retention leading to severe hyponatremia, which can cause seizures, cerebral edema, or even death. Allergic reactions ranging from rash to anaphylaxis are also serious. Patients should be monitored for rapid weight gain, low serum sodium, and any signs of hypersensitivity.

Minurin is contraindicated in individuals with known hypersensitivity to desmopressin or any of its excipients. It should be avoided in patients with uncontrolled hypertension, severe renal impairment, or those taking other potent antidiuretic agents that could precipitate dangerous fluid overload.